Evidence map›Paper›PMID 35163593›Full record

ArticleInternational journal of molecular sciences2022

Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.

Jih-Tung Pai, Xing-Han Chen, Yann-Lii Leu, Meng-Shih Weng

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Heliyon · 2022
    Article
  9. An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jih-Tung PaiDivision of Hematology and Oncology, Tao-Yuan General Hospital, Ministry of Health and Welfare, Taoyuan City 33004, Taiwan.
Xing-Han ChenDepartment of Nutritional Science, Fu Jen Catholic University, New Taipei City 24205, Taiwan.
Yann-Lii LeuGraduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan.ORCID 0000-0002-1649-6798
Meng-Shih WengDepartment of Nutritional Science, Fu Jen Catholic University, New Taipei City 24205, Taiwan.
Fu Jen Catholic University · TWChang Gung University · TWTao Yuan General Hospital · TW

Funding

Ministry of Science and Technology MOST 109-2320-B-030-011Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan PTH108022
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer with a poor prognosis. The incidence and mortality rate of TNBC are frequently found in younger women. Due to the absence of a good therapeutic strategy, effective remedies for inhibiting TNBC have been developed for improving the cure rate. Epithelial-to-mesenchymal transition (EMT) is a critical mechanism to regulate cancer cell motility and invasion. Furthermore, ectopic expression of EMT molecules correlates with the metastasis and poor prognosis of TNBC. Targeting EMT might be a strategy for the therapy and prevention of TNBC. Propolin G, an active c-prenylflavanone in Taiwanese propolis, has been shown to possess anti-cancer activity in many cancers. However, the anti-metastasis activity of propolin G on TNBC is still unclear. The present study showed that the migration and invasion activities of TNBC cells was suppressed by propolin G. Down-regulated expression of Snail and vimentin and up-regulated expression of E-cadherin were dose- and time-dependently observed in propolin G-treated MDA-MB-231 cells. Propolin G inhibited Snail and vimentin expressions via the signaling pathways associated with post-translational modification. The activation of glycogen synthase kinase 3β (GSK-3β) by propolin G resulted in increasing GSK-3β interaction with Snail. Consequently, the nuclear localization and stability of Snail was disrupted resulting in promoting the degradation. Propolin G-inhibited Snail expression and the activities of migration and invasion were reversed by GSK-3β inhibitor pretreatment. Meanwhile, the outcomes also revealed that histone deacetylase 6 (HDAC6) activity was dose-dependently suppressed by propolin G. Correspondently, the amounts of acetyl-α-tubulin, a down-stream substrate of HDAC6, were increased. Dissociation of HDAC6/Hsp90 with vimentin leading to increased vimentin acetylation and degradation was perceived in the cells with the addition of propolin G. Moreover, up-regulated expression of acetyl-α-tubulin by propolin G was attenuated by HDAC6 overexpression. On the contrary, down-regulated expression of vimentin, cell migration and invasion by propolin G were overturned by HDAC6 overexpression. Conclusively, restraint cell migration and invasion of TNBC by propolin G were activated by the expression of GSK-3β-suppressed Snail and the interruption of HDAC6-mediated vimentin protein stability. Aiming at EMT, propolin G might be a potential candidate for TNBC therapy.

Indexed as

Cell Line, TumorCoumarinsEpithelial-Mesenchymal TransitionFemaleFlavanonesGlycogen Synthase Kinase 3 betaHistone Deacetylase 6HumansNeoplasm ProteinsProteolysisTriple Negative Breast NeoplasmsVimentinCoumarinsFlavanonesGlycogen Synthase Kinase 3 betaGSK3B protein, humanHDAC6 protein, humanHistone Deacetylase 6Neoplasm Proteinspropolin GVimentinVIM protein, humanepithelial-to-mesenchymal transition (EMT)glycogen synthase kinase 3β(GSK-3β)histone deacetylase 6 (HDAC6)propolin Gtriple-negative breast cancer (TNBC)

Identifiers

PMID35163593
PMCPMC8835855
OpenAlexW4210771115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.